scholarly journals Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial

2018 ◽  
Vol 21 (7) ◽  
pp. 654-660 ◽  
Author(s):  
Darías Holgado ◽  
Thomas Zandonai ◽  
Mikel Zabala ◽  
James Hopker ◽  
Pandelis Perakakis ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Physical Performance ◽  
Sustained Attention ◽  
Controlled Trial ◽  
Time Trial ◽  
Cycling Time Trial ◽  
Randomised Controlled ◽  
Cycling Time

Influence of 2-Weeks Ingestion of High Chlorogenic Acid Coffee on Mood State, Performance, and Postexercise Inflammation and Oxidative Stress: A Randomized, Placebo-Controlled Trial

2018 ◽  
Vol 28 (1) ◽  
pp. 55-65 ◽  
Author(s):  
David C. Nieman ◽  
Courtney L. Goodman ◽  
Christopher R. Capps ◽  
Zack L. Shue ◽  
Robert Arnot
Keyword(s):  
Oxidative Stress ◽  
Chlorogenic Acid ◽  
Mood State ◽  
Controlled Trial ◽  
Time Trial ◽  
Cycling Performance ◽  
Cycling Time Trial ◽  
Reducing Ability ◽  
And Oxidative Stress ◽  
Cycling Time

This study measured the influence of 2-weeks ingestion of high chlorogenic acid (CQA) coffee on postexercise inflammation and oxidative stress, with secondary outcomes including performance and mood state. Cyclists (N = 15) were randomized to CQA coffee or placebo (300 ml/day) for 2 weeks, participated in a 50-km cycling time trial, and then crossed over to the opposite condition with a 2-week washout period. Blood samples were collected pre- and postsupplementation, and immediately postexercise. CQA coffee was prepared using the Turkish method with 30 g lightly roasted, highly ground Hambela coffee beans in 300 ml boiling water, and provided 1,066 mg CQA and 474 mg caffeine versus 187 mg CQA and 33 mg caffeine for placebo. Plasma caffeine was higher with CQA coffee versus placebo after 2-weeks (3.3-fold) and postexercise (21.0-fold) (interaction effect, p < .001). Higher ferric reducing ability of plasma (FRAP) levels were measured after exercise with CQA coffee versus placebo (p = .01). No differences between CQA coffee and placebo were found for postexercise increases in plasma IL-6 (p = .74) and hydroxyoctadecadienoic acids (9 + 13 HODEs) (p = .99). Total mood disturbance (TMD) scores were lower with CQA coffee versus placebo (p = .04). 50-km cycling time performance and power did not differ between trials, with heart rate and ventilation higher with CQA coffee, especially after 30 min. In summary, despite more favorable TMD scores with CQA coffee, these data do not support the chronic use of coffee highly concentrated with chlorogenic acids and caffeine in mitigating postexercise inflammation or oxidative stress or improving 50-km cycling performance.

scholarly journals Early pulmonary rehabilitation after acute exacerbation of COPD: a randomised controlled trial

2020 ◽  
Vol 6 (1) ◽  
pp. 00173-2019 ◽  
Author(s):  
Jakob L. Kjærgaard ◽  
Carsten B. Juhl ◽  
Peter Lange ◽  
Jon T. Wilcke
Keyword(s):  
Randomised Controlled Trial ◽  
Acute Exacerbation ◽  
Physical Performance ◽  
Pulmonary Rehabilitation ◽  
Controlled Trial ◽  
Stable Phase ◽  
Walk Test ◽  
Acute Exacerbation Of Copd ◽  
Exacerbation Of Copd ◽  
Randomised Controlled

ObjectivesThe aim of this study was to establish whether early pulmonary rehabilitation after severe exacerbation of chronic obstructive pulmonary disease (COPD) reduces mortality and hospital admissions, and increases physical performance and quality of life compared to rehabilitation initiated later in the stable phase of COPD.MethodsIn a randomised controlled trial of 150 patients hospitalised with an exacerbation of COPD, participants were allocated to pulmonary rehabilitation either within 2 weeks after discharge or the same rehabilitation programme but initiated 2 months after discharge.ResultsEarly pulmonary rehabilitation did not prolong time to first hospital admission or time to death (hazard ratio 0.79, 95% CI 0.47–1.23, p=0.33) compared to rehabilitation in stable phase. However, 2 months after inclusion, pulmonary rehabilitation resulted in a significantly better improvement in the incremental shuttle walk test (33.9 m, 95% CI 4.18–63.7, p=0.02) compared to that in the stable phase. The difference in the endurance shuttle walk test was of borderline significance (140 s, 95% CI −2.03–282.76, p=0.05), but there was no significant difference concerning the COPD assessment test (−1.43 points, 95% CI −3.44–0.59, p=0.17).ConclusionEarly pulmonary rehabilitation after acute exacerbation of COPD led to a faster improvement in physical performance compared to rehabilitation initiated later in the stable phase, but did not improve survival or prolong time to hospital readmission.

scholarly journals Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial

2017 ◽  
Author(s):  
Darias Manuel Holgado Nuñez ◽  
Thomas Zandonai ◽  
Mikel Zabala ◽  
James Hopker ◽  
Pandelis Perakakis ◽  
...  
Keyword(s):  
Sustained Attention ◽  
Power Output ◽  
Cognitive Task ◽  
Average Power ◽  
Time Trial ◽  
Placebo Condition ◽  
Time Frequency ◽  
Cycling Time Trial ◽  
Oddball Task ◽  
Cycling Time

Objectives: To investigate the effect of tramadol on performance during a 20-min cycling time-trial (Experiment 1), and to test whether sustained attention would be impaired during cycling after tramadol intake (Experiment 2).Design: randomized, double-blind, placebo controlled trial.Methods: In Experiment 1, participants completed a cycling time-trial, 120-min after they ingested either tramadol or placebo. In Experiment 2, participants performed a visual Oddball task during the time-trial. Electroencephalography measures (EEG) were recorded throughout the session.Results: In Experiment 1, average time-trial power output was higher in the tramadol vs. placebo condition (tramadol: 220 watts vs. placebo: 209 watts; p &lt; 0.01). In Experiment 2, no differences between conditions were observed in the average power output (tramadol: 234 watts vs. placebo: 230 watts; p &gt; 0.05). No behavioural differences were found between conditions in the Oddball task. Crucially, the time frequency analysis in Experiment 2 revealed an overall lower target-locked power in the beta-band (p &lt; 0.01), and higher alpha suppression (p &lt; 0.01) in the tramadol vs. placebo condition. At baseline, EEG power spectrum was higher under tramadol than under placebo in Experiment 1 while the reverse was true for Experiment 2.Conclusions: Tramadol improved cycling power output in Experiment 1, but not in Experiment 2, which may be due to the simultaneous performance of a cognitive task. Interestingly enough, the EEG data in Experiment 2 pointed to an impact of tramadol on stimulus processing related to sustained attention.Trial registration: EudraCT number: 2015-005056-96.

Sign in / Sign up

Export Citation Format

Share Document